Deepeye Medical secures €2.5 million from investors to strengthen AI platform for eye health

Bayern Kapital is investing EUR 2.5 million in deepeye Medical, a start-up that is revolutionizing retinal therapy with AI. The technology aims to improve the treatment of age-related macular degeneration.

Landshut - Bayern Kapital, an experienced investor in high-tech financing, has invested in deepeye Medical, a Munich-based start-up specializing in healthcare technology. Deepeye Medical is dedicated to improving retinal therapy with the help of artificial intelligence (AI). YZR Capital as lead investor and ARVE Capital also participated in this current seed financing round. Together with research and development grants, the company has around 2.5 million euros at its disposal to further develop the AI-based software.

We are continuously developing our product and aim to offer a patient-oriented therapy decision aid with just one click by 2024. Our vision is to prevent one million people from going blind by 2030

Ratko Petrovic, co-founder of deepeye Medical

Deepeye Medical was founded in 2021 and aims to improve the treatment of age-related macular degeneration (AMD). AMD is a serious eye disease and the most common cause of blindness in the EU and the USA. The start-up uses an algorithm based on three-dimensional eye tomography to analyze retinal images. This enables doctors to create personalized treatment suggestions and increase the chances of successful therapy. The algorithm has learned from hundreds of thousands of retinal scans and provides data-based information to better assess disease activity and progression. The software complements clinical expertise and helps treating physicians to better understand the clinical picture and optimize therapy intervals. It also facilitates patient education.

Deepeye Medical has already achieved success in collaboration with major pharmaceutical companies such as Novartis, Bayer and Roche. The AI platform is also used by other companies and physicians to gain valuable insights from existing therapy data.

The investment in deepeye Medical is an investment in the future of vision and in the quality of life of patients. Deepeye Medical shows great potential to become an important component of successful retinal treatments.

Monika Steger, Managing Director of Bayern Kapital

Deepeye Medical plans to further develop its AI-based platform and offer patient-centered therapy decision support by 2024. Their goal is to save one million people from blindness by 2030 by providing eye doctors with crucial data-driven information.

Bayern Kapital is the venture/growth capital company of the Free State of Bavaria and supports innovative high-tech companies in various growth phases with equity capital. With a portfolio of over 100 companies, Bayern Kapital has already supported numerous success stories and makes a significant contribution to the creation of jobs in sustainable sectors. Examples of successful investments include companies such as EOS, Proglove, Fazua, SimScale and many others.